2025-05-13 - Analysis Report
Okay, here's an analysis of Merck & Co. Inc. (MRK) based on the provided information, formatted for a concise report.

## Merck & Co. Inc. (MRK) Analysis

**Merck & Co. Inc. is a global pharmaceutical company focused on developing medicines and vaccines for a range of diseases.**

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (MRK):** 21.62%
*   **Cumulative Return (VOO):** 93.97%
*   **Spread:** -72.35% (MRK significantly underperformed the S&P 500)
*   **Relative Spread:** 7.6 (This indicates that MRK's underperformance is near the lower end of its historical range relative to the S&P 500.)

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta | Cap(B) |
|------------|---------|--------|---------|------|--------|
| 2015-2017  | 10.0%   | 58.6%  | -22.0%  | 0.1  | 108.3  |
| 2016-2018  | 49.0%   | 66.4%  | 27.0%   | 0.4  | 151.6  |
| 2017-2019  | 48.0%   | 66.4%  | 14.0%   | 0.9  | 185.4  |
| 2018-2020  | 26.0%   | 66.4%  | -4.0%   | 0.7  | 172.0  |
| 2019-2021  | 4.0%    | 65.6%  | -56.0%  | 0.5  | 175.1  |
| 2020-2022  | 20.0%   | 69.3%  | 11.0%   | 0.5  | 261.6  |
| 2021-2023  | 43.0%   | 69.3%  | 22.0%   | 0.3  | 264.2  |
| 2022-2024  | -3.0%   | 69.3%  | -24.0%  | 0.2  | 247.7  |
| 2023-2025  | -48.0%  | 70.2%  | -80.0%  | 0.3  | 202.0  |

*   **Analysis:**  The historical alpha values are highly variable, indicating periods of both outperformance and underperformance compared to the market.  Beta values are generally low, suggesting lower volatility than the market. The recent years (2019-2025) show significant underperformance (negative alpha) and a substantial drop in CAGR, alongside high MDD values, indicating considerable risk. The market cap has fluctuated, reflecting the company's performance changes.

### 2. Recent Price Action

*   **Current Price:** 80.43
*   **Last Market Data:** Price Change=5.87
*   **5-day Moving Average:** 78.44
*   **20-day Moving Average:** 80.24
*   **60-day Moving Average:** 86.00

*   **Analysis:** The price is currently above both the 5-day and 20-day moving averages, but below the 60-day moving average. The significant recent price change suggests a short-term positive momentum.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3676 (Low Risk)
*   **RSI:** 53.55 (Neutral)
*   **PPO:** -0.05 (Slightly Bearish)
*   **Recent (20-day) Relative Spread Change:** -9.4 (Short-term Decline)
*   **Expected Return:** -52.9% (Significant negative projected outperformance vs. S&P 500 over the long term.)

*   **Analysis:** The MRI suggests a low-risk environment for the stock. The RSI is neutral, not indicating overbought or oversold conditions. The negative PPO and declining relative spread suggest some bearish momentum. The large negative expected return is concerning, suggesting the model anticipates substantial underperformance compared to the S&P 500.

### 4. Recent News & Events

*   **Summary:** Recent news indicates potential business developments, regulatory changes, and market events are influencing MRK's stock volatility. Analysts are discussing the company's performance in the context of industry and global factors.

*   **Analysis:** These news snippets suggest increased uncertainty and potential for significant price swings. Investors should closely monitor news releases and company announcements.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출      |
|--------------|------|-----------|
| 2025-05-02   | 2.01 | 15.53 B$  |
| 2024-11-06   | 1.25 | 16.66 B$  |
| 2024-08-05   | 2.15 | 16.11 B$  |
| 2024-05-03   | 1.88 | 15.78 B$  |
| 2025-05-02   | 1.88 | 15.78 B$  |

*   **Analysis:**  Earnings per share (EPS) have fluctuated. Revenue has shown some variability. The latest EPS and revenue figures show signs of flattening.

### 6. Financial Information

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-03-31 | $15.53B  | 77.98%        |
| 2024-12-31 | $15.62B  | 75.50%        |
| 2024-09-30 | $16.66B  | 75.51%        |
| 2024-06-30 | $16.11B  | 76.76%        |
| 2024-03-31 | $15.78B  | 77.56%        |

| Quarter    | Equity   | ROE      |
|------------|----------|----------|
| 2025-03-31 | $48.34B  | 10.51%   |
| 2024-12-31 | $46.31B  | 8.08%    |
| 2024-09-30 | $44.50B  | 7.09%    |
| 2024-06-30 | $43.58B  | 12.52%   |
| 2024-03-31 | $40.36B  | 11.80%   |

*   **Analysis:** Revenue has been relatively stable over the past year. Profit margins are consistently high, indicating strong profitability. Equity has been growing steadily. Return on Equity (ROE) has fluctuated, but remains at reasonable levels, suggesting efficient use of shareholder equity.

### 7. Overall Summary

Merck & Co. Inc. (MRK) shows a mixed picture. While the company maintains strong profitability and a low-risk profile according to the Market Risk Indicator, it has significantly underperformed the S&P 500. The negative expected return and volatile alpha values raise concerns about future performance. Recent news suggests potential for volatility. Investors should carefully weigh the company's financial strengths against its underperformance and market uncertainties. Close monitoring of news and financial reports is advised.
